Monte Rosa Therapeutics Inc’s filing revealed that its 10% Owner Versant Venture Capital VI, L. unloaded Company’s shares for reported $0.87 million on Oct 28 ’24. In the deal valued at $9.66 per share,89,990 shares were sold. As a result of this transaction, Versant Venture Capital VI, L. now holds 2,007,948 shares worth roughly $11.36 million.
Then, Versant Venture Capital VI, L. sold 67,905 shares, generating $621,801 in total proceeds. Upon selling the shares at $9.16, the 10% Owner now owns 1,573,453 shares.
Before that, Wallace Owen B. bought 20,000 shares. Monte Rosa Therapeutics Inc shares valued at $240,000 were divested by the Officer at a price of $12.00 per share.
Wells Fargo downgraded its Monte Rosa Therapeutics Inc [GLUE] rating to an Equal weight from a an Overweight in a research note published on December 19, 2024; the price target was decreased to $11 from $14. A number of analysts have revised their coverage, including Wedbush’s analysts, who began to cover the stock in mid February with a ‘”an Outperform”‘ rating. Wells Fargo also remained covering GLUE and has increased its forecast on January 03, 2023 with a “an Overweight” recommendation from previously “an Equal weight” rating. UBS started covering the stock on October 13, 2022. It rated GLUE as “a Buy”.
Price Performance Review of GLUE
On Monday, Monte Rosa Therapeutics Inc [NASDAQ:GLUE] saw its stock fall -0.70% to $5.66. Over the last five days, the stock has lost -21.06%. Monte Rosa Therapeutics Inc shares have fallen nearly -18.44% since the year began. Nevertheless, the stocks have fallen -19.77% over the past one year. While a 52-week high of $12.40 was reached on 01/03/25, a 52-week low of $3.21 was recorded on 01/13/25. SMA at 50 days reached $8.18, while 200 days put it at $5.92.
Levels Of Support And Resistance For GLUE Stock
The 24-hour chart illustrates a support level at 5.46, which if violated will result in even more drops to 5.26. On the upside, there is a resistance level at 5.78. A further resistance level may holdings at 5.90. The Relative Strength Index (RSI) on the 14-day chart is 30.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.96, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.54%. Stochastics %K at 9.52% indicates the stock is a buying.
How much short interest is there in Monte Rosa Therapeutics Inc?
A steep rise in short interest was recorded in Monte Rosa Therapeutics Inc stocks on 2024-12-31, dropping by -1.91 million shares to a total of 9.14 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 11.05 million shares. There was a decline of -20.89%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 15, 2022 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $20 price target.
